Management of Male Breast Cancer: ASCO Guideline
Top Cited Papers
- 1 June 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (16), 1849-1863
- https://doi.org/10.1200/jco.19.03120
Abstract
To develop recommendations concerning the management of male breast cancer. ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. Twenty-six descriptive reports or observational studies met eligibility criteria and formed the evidentiary basis for the recommendations. Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of five years; those with a contraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may be offered an additional five years of therapy. Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence, but could still receive these agents to prevent or treat osteoporosis. Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis or rapidly progressive disease. Targeted systemic therapy may be used to treat advanced or metastatic cancer using the same indications and combinations offered to women. Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy regardless of genetic predisposition; contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation. Breast magnetic resonance imaging is not recommended routinely. Genetic counseling and germline genetic testing of cancer predisposition genes should be offered to all men with breast cancer.This publication has 67 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effectsAnnals of Oncology, 2011
- Breast cancer in men in the United StatesCancer, 2010
- Aromatase inhibition in male breast cancer patients: biological and clinical implicationsAnnals of Oncology, 2010
- Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation CarriersJNCI Journal of the National Cancer Institute, 2007
- PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneNature Genetics, 2006
- Adjuvant systemic therapy for male breast carcinomaCancer, 2005
- Experiences of men with breast cancer: an exploratory focus group studyBritish Journal of Cancer, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesAmerican Journal of Human Genetics, 2003
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002